177 related articles for article (PubMed ID: 37542044)
1. Single-cell trajectory analysis reveals a CD9 positive state to contribute to exit from stem cell-like and embryonic diapause states and transit to drug-resistant states.
Li X; Poire A; Jeong KJ; Zhang D; Chen G; Sun C; Mills GB
Cell Death Discov; 2023 Aug; 9(1):285. PubMed ID: 37542044
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer.
Singh B; Sarli VN; Milligan RD; Kinne HE; Shamsnia A; Washburn LJ; Addanki S; Lucci A
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046697
[TBL] [Abstract][Full Text] [Related]
3. Resistance to BET inhibitors in lung adenocarcinoma is mediated by casein kinase phosphorylation of BRD4.
Calder J; Nagelberg A; Luu J; Lu D; Lockwood WW
Oncogenesis; 2021 Mar; 10(3):27. PubMed ID: 33712563
[TBL] [Abstract][Full Text] [Related]
4. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions.
Wu T; Wang G; Chen W; Zhu Z; Liu Y; Huang Z; Huang Y; Du P; Yang Y; Liu CY; Cui L
Cell Death Dis; 2018 Feb; 9(3):315. PubMed ID: 29472532
[TBL] [Abstract][Full Text] [Related]
5. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C; Galan-Moya EM; Corrales-Sanchez V; Noblejas-Lopez MDM; Burgos M; Domingo B; Montero JC; Gomez-Juarez M; Picazo-Martinez MG; Esparis-Ogando A; Pandiella A; Ocaña A
Cancer Lett; 2020 Oct; 491():50-59. PubMed ID: 32735909
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticles Loaded with the BET Inhibitor JQ1 Block the Growth of Triple Negative Breast Cancer Cells In Vitro and In Vivo.
Maggisano V; Celano M; Malivindi R; Barone I; Cosco D; Mio C; Mignogna C; Panza S; Damante G; Fresta M; Andò S; Russo D; Catalano S; Bulotta S
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905936
[TBL] [Abstract][Full Text] [Related]
8. Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer.
Luan W; Pang Y; Li R; Wei X; Jiao X; Shi J; Yu J; Mao H; Liu P
Onco Targets Ther; 2019; 12():8063-8074. PubMed ID: 31632060
[TBL] [Abstract][Full Text] [Related]
9. Effects of bromodomain and extra-terminal inhibitor JQ1 and interleukin-6 on breast cancer cells.
Sharifhoseini A; Heshmati M; Soltani A; Entezam M; Shirzad H; Sedehi M; Judd BA; Jami MS; Ghatrehsamani M
Mol Biol Rep; 2023 Oct; 50(10):8319-8328. PubMed ID: 37589934
[TBL] [Abstract][Full Text] [Related]
10. Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer.
Yellapu NK; Ly T; Sardiu ME; Pei D; Welch DR; Thompson JA; Koestler DC
BMC Cancer; 2022 Jun; 22(1):627. PubMed ID: 35672711
[TBL] [Abstract][Full Text] [Related]
11. LIN9 confers paclitaxel resistance in triple negative breast cancer cells by upregulating CCSAP.
Lai H; Wang R; Li S; Shi Q; Cai Z; Li Y; Liu Y
Sci China Life Sci; 2020 Mar; 63(3):419-428. PubMed ID: 31420851
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Giordano A; Liu Y; Armeson K; Park Y; Ridinger M; Erlander M; Reuben J; Britten C; Kappler C; Yeh E; Ethier S
PLoS One; 2019; 14(11):e0224420. PubMed ID: 31751384
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of BET inhibitors in androgen-receptor-expressing triple-negative breast cancer.
Park IH; Yang HN; Jeon SY; Hwang JA; Kim MK; Kong SY; Shim SH; Lee KS
Sci Rep; 2019 Sep; 9(1):13305. PubMed ID: 31527644
[TBL] [Abstract][Full Text] [Related]
14. EGFR signaling confers resistance to BET inhibition in hepatocellular carcinoma through stabilizing oncogenic MYC.
Yin Y; Sun M; Zhan X; Wu C; Geng P; Sun X; Wu Y; Zhang S; Qin J; Zhuang Z; Liu Y
J Exp Clin Cancer Res; 2019 Feb; 38(1):83. PubMed ID: 30770740
[TBL] [Abstract][Full Text] [Related]
15. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
[TBL] [Abstract][Full Text] [Related]
16. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
[No Abstract] [Full Text] [Related]
17. Vitamin C supplementation expands the therapeutic window of BETi for triple negative breast cancer.
Mustafi S; Camarena V; Qureshi R; Yoon H; Volmar CH; Huff TC; Sant DW; Zheng L; Brothers SP; Wahlestedt C; Slingerland J; Wang G
EBioMedicine; 2019 May; 43():201-210. PubMed ID: 30975544
[TBL] [Abstract][Full Text] [Related]
18. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
19. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
20. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
Rossi T; Zamponi R; Chirico M; Pisanu ME; Iorio E; Torricelli F; Gugnoni M; Ciarrocchi A; Pistoni M
J Exp Clin Cancer Res; 2023 Jan; 42(1):7. PubMed ID: 36604676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
